The liberation of CD44 by Cichy, Joanna & Puré, Ellen
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
JCB
 
 
 
The Rockefeller University Press, 0021-9525/2003/06/839/5 $8.00
The Journal of Cell Biology,
 
 
 
Volume 161, Number 5, June 9, 2003 839–843
http://www.jcb.org/cgi/doi/10.1083/jcb.200302098 839
 
Mini-Review
 
The liberation of CD44
 
Joanna Cichy
 
1
 
 and Ellen Puré
 
2,3
 
1
 
Jagiellonian University, Faculty of Biotechnology, 30-387 Kraków, Poland
 
2
 
The Wistar Institute, Philadelphia, PA 19104
 
3
 
The Ludwig Institute for Cancer Research, New York, NY 10158
 
CD44 was once thought to simply be a transmembrane
 
adhesion molecule that also played a role in the metabolism
of its principal ligand hyaluronan. Investigations of CD44
 
over the past 
 
 
 
20 yr have established additional functions
for CD44, including its capacity to mediate inﬂammatory
cell function and tumor growth and metastasis. It has also
become evident that intricate posttranslational modiﬁca-
tions of CD44 regulate the afﬁnity of the receptor for its
ligands. In this review, we focus on emerging evidence
 
that functional fragments of the cytoplasmic and ecto-
domain of CD44 can be liberated by enzymatic modiﬁcation
of cell surfaces as well as of cell-associated matrix. Based
on the evidence discussed, we propose that CD44 exists in
three phases, as a transmembrane receptor, as an integral
component of the matrix, and as a soluble protein found
in body ﬂuids, each with biologically signiﬁcant functions
of which some are shared and some distinct. Thus, CD44
represents a model for understanding posttranslational
processing and its emerging role as a general mechanism
for regulating cell behavior.
 
Cell surface adhesion receptors anchor cells to their sur-
roundings, regulate cell mobility, and provide cells with critical
sensors of their environment. Cell adhesion molecules are
subject to regulation at multiple levels, including transcription,
alternative RNA splicing, and posttranslational modifications
such as phosphorylation, glycosylation, and sulfation. Pro-
teolytic processing has also emerged as a key mechanism
underlying the regulation of several cell surface adhesion mol-
ecules, including members of the selectin and cadherin families.
CD44 is a broadly distributed transmembrane glycopro-
tein that plays a critical role in a variety of cellular behav-
iors, including adhesion, migration, invasion, and survival.
CD44 mediates cell–cell and cell–matrix interactions in a
large part through its affinity for hyaluronan (HA),* a
glycosaminoglycan constituent of extracellular matrices, but
also potentially through its affinity for other ligands such
as osteopontin, collagens, and matrix metalloproteinases
(MMPs). A soluble form of CD44 has been detected in the
circulation and other body fluids. In this review, we focus on
the mounting evidence that limited proteolysis liberates
functional fragments of both the cytoplasmic (intracellular)
domain as well as the extracellular domain of CD44. Further-
more, we review recent evidence that CD44 released from
cells can accumulate as an integral component of cell-associated
matrices. We also address the issue of the derivation of soluble
CD44 that accumulates in the fluid phase under pathologic
conditions that are associated with increased proteolytic
activity and matrix remodeling. Based on current evidence,
we propose that CD44 can exist in three distinct physical
phases, as a transmembrane cell surface receptor, an integral
component of the matrix, and in a fluid phase, each with the
potential for being functionally significant (Table I).
 
Structure and function of transmembrane CD44
 
CD44 is encoded by a single gene, but multiple isoforms of
CD44 are generated by alternative RNA splicing. The gene
for CD44 contains 20 exons, 12 of which are expressed by
the most common form of CD44, referred to as standard or
hematopoietic CD44. The nonvariant exons encode for an
extracellular domain, a transmembrane domain, and an
intracellular domain. Isoforms of CD44 are generated by the
insertion of alternative exons (V1–V11) at a single site
within the membrane-proximal portion of the extracellular
domain (for reviews see Naor et al., 1997; Ponta et al.,
2003). The predominant 72–amino acid cytoplasmic domain
can also be replaced by an alternatively spliced shorter form.
Differential posttranslational modifications, including glyco-
sylation and the attachment of glycosaminoglycans, generate
additional structural diversity of CD44.
The regulation of the affinity of cell adhesion molecules is
prerequisite for regulating cell–cell and cell–matrix interactions
mediated by broadly expressed receptors that are exposed
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continuously to their ligands. Most primary cells express
CD44 but in a low affinity state that does not exhibit a capacity
to bind to HA. Cellular activation can induce a transition of
CD44 to a high affinity state that mediates binding to HA.
Transition from the “inactive” low affinity state to the “active”
high affinity state of CD44 on leukocytes can be induced by
the ligation of antigen receptors, and on leukocytes and epi-
thelial and other mesenchymal cells by soluble factors includ-
ing cytokines (Levesque et al., 1997; Cichy and Puré, 2000;
Brown et al., 2001). A variety of mechanisms have been im-
plicated in the transition from inactive to active forms of
CD44, including variant exon usage, receptor oligomeriza-
tion, glycosylation, and sulfation (for review see Ponta et al.,
2003). However, to date, no data are available to indicate how
these posttranslational modifications alter either the configu-
ration of the receptor, its three-dimensional structure, or its
molecular interactions with other moieties to modify the af-
finity of the receptor for HA. Functional activation of CD44,
as opposed to regulation of receptor solely at the level of tran-
scription, presumably provides for more efficient recruitment
of CD44–HA interactions in mediating cell–cell and cell–
matrix interactions as required, for example, after exposure to
an inflammatory stimulus. In contrast to normal primary cells,
many tumor-derived cells express CD44 in a high affinity
state with capacity to mediate constitutive binding to HA (for
review see Naor et al., 1997). In addition to being a receptor
for HA, CD44 can interact with several ECM proteins, such
as fibronectin and collagens, growth factors, cytokines and
chemokines, as well as metalloproteinases (for reviews see
Naor et al., 1997; Ponta et al., 2003), but less is known about
the regulation of the interactions of these ligands with CD44.
Transmembrane CD44 serves multiple roles, including
mediating the metabolism of HA (Kaya et al., 1997), in the
regulation of tumor invasiveness and in the modulation of
inflammatory cell function. Alterations in CD44 expression
and structure have been documented in many types of can-
cer and are related to tumor dissemination (for reviews see
Naor et al., 1997; Ponta et al., 2003). Moreover, targeted
deletion of CD44 prevented dissemination of some tumors
(Weber et al., 2002). Most of the known effects of CD44 on
cell adhesion, migration, and metastasis are intimately asso-
ciated with its capacity to promote cell attachment to HA
(for review see Naor et al., 1997). Recent findings suggest
that CD44 might also promote metastasis through its associ-
ation with other molecules. For example, CD44 provides a
 
docking site for MMP-9 on the surface of melanoma and
carcinoma cells (Yu and Stamenkovic, 1999) and thus can
indirectly contribute to pericellular proteolysis to regulate
tumor cell motility, growth factor activation, angiogenesis,
as well as survival mechanisms. Furthermore, it was recently
demonstrated that CD44-mediated localization of MMP-9
to the surface of some tumor cell lines results in the activa-
tion of TGF-
 
 
 
 and promotion of tumor invasion and angio-
genesis (Yu and Stamenkovic, 2000). Interestingly, increased
levels of soluble CD44 (sCD44) have been detected in
plasma from patients with some tumors (Okamoto et al.,
2002). This may reflect the increase in proteolytic activity
and matrix remodeling that is associated with tumor growth
and metastasis.
CD44 does not appear to play a critical role in the im-
mune system under homeostatic conditions. However, in-
flammation is associated with increased expression of cell
surface CD44 on hematopoietic cells. Activation of T cells
augments CD44-mediated HA binding and contributes to
targeting of T cells to inflammatory sites (DeGrendele et al.,
1997). Based on the detection of elevated numbers of circu-
lating T cells expressing activated CD44 in conditions of
chronic inflammation, it has been suggested that functional
activation of CD44 on lymphocytes may contribute to
chronic inflammatory diseases (Estess et al., 1998). A critical
role for CD44 in inflammation is supported by studies using
anti-CD44 antibodies and CD44-deficient mice. Adminis-
tration of anti-CD44 antibodies to mice retarded cutaneous
delayed-type hypersensitivity (Camp et al., 1993) and pro-
tected mice against experimental arthritis (Mikecz et al.,
1995). In addition, anti-CD44 antibodies protected mice
from the pathology associated with acute infection with 
 
Toxo-
plasma gondii
 
 (Blass et al., 2001). Although minimal de-
fects were noted in unchallenged CD44-deficient animals
(Schmits et al., 1997), inflammatory responses in CD44-
deficient mice are significantly altered compared with wild-
type mice. For example, the extent of atherosclerotic lesions
in hypercholesterolemic (apolipoprotein E–deficient, apoE
 
 
 
/
 
 
 
)
mice that were also deficient in CD44 was markedly re-
duced when compared with apoE
 
 
 
/
 
 
 
 mice expressing CD44
(Cuff et al., 2001). Reduced atherogenesis was associated
with the inhibition of macrophage recruitment and inhibi-
tion of macrophage and vascular smooth muscle cell activa-
tion in atherosclerotic lesions. Furthermore, the deletion of
one particular isoform, CD44v7, protected against experi-
 
Table I. 
 
Potential mechanisms for the generation and function of cell surface, matrix-associated, and fluid phase CD44
Form of CD44 Potential mechanisms of generation Known and proposed functions
 
Transmembrane Synthesized as type-I integral transmembrane 
protein
1. Cell–cell adhesion
2. Cell–matrix adhesion
3. Signal transduction
4. Pericellular matrix assembly
5. Hyaluronan metabolism
Matrix-associated ectodomain 1. Shedding of transmembrane form
2. Secretion of alternatively spliced form
1. Pericellular matrix assembly
2. Integral component of ECM
3. Agonist/antagonist of transmembrane form
Fluid phase 1. Shedding of transmembrane form
2. Secretion of alternatively spliced form
3. Enzymatic liberation from matrix
Agonist/antagonist of transmembrane- and matrix-
associated forms
Intracellular cytoplasmic domain Presenilin-dependent cleavage of truncated 
transmembrane form
Regulation of transcription after nuclear 
translocationT
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mental colitis (Wittig et al., 2000). Targeted disruption of
CD44, in contrast, resulted in impaired resolution of the in-
flammatory response after bleomycin-induced lung injury,
resulting in death (Teder et al., 2002). CD44 deficiency un-
der these conditions resulted in excessive accumulation of
HA in bronchoalveolar lavage fluid, impaired clearance of
apoptotic neutrophils, and a defect in TGF-
 
 
 
 activation.
Together, these data suggest that CD44 is pivotal to the pro-
gression of inflammation and fibrosis.
 
Potential mechanisms for shedding of CD44 
from the cell surface
 
sCD44 has been detected in serum, lymph, arthritic synovial
fluid, and bronchoalveolar lavage (Katoh et al., 1994, 1999;
Shi et al., 2001). Malignant disease and immune activation
and inflammation are often associated with increased plasma
levels of sCD44, whereas immunodeficiency correlates with
low plasma levels of sCD44. These findings indicate that re-
lease of CD44 correlates with enhanced local proteolytic ac-
tivity and matrix remodeling and have generated interest in
CD44 as a potential biomarker for tumor growth and me-
tastasis and immune activation and inflammation. Expres-
sion of an alternatively spliced form of CD44 lacking the
transmembrane and cytoplasmic domains of the receptor has
been described, providing a mechanism for the de novo syn-
thesis of sCD44 (Yu and Toole, 1996). However, the major
mechanism invoked in the production of sCD44 involves
proteolytic cleavage of cell surface CD44 (Okamoto et al.,
1999). CD44 is released from cells constitutively, but en-
hanced release can be induced by phorbol esters, a calcium
ionophore, ionomycin (DeGrendele et al., 1997), cytokines
(Ristamaki et al., 1997), as well as bacterial- and leukocyte-
derived proteinases (Cichy et al., 2002; Lazaar et al., 2002).
Release of sCD44 is also likely to be ligand inducible, as an-
tibody cross-linking of CD44 leads to release of sCD44
(Camp et al., 1993; Shi et al., 2001). Concomitant with
CD44 shedding, cytoskeletal reorganization occurs (Shi et
al., 2001). Pharmacological disruption of actin assembly re-
duced CD44 shedding, whereas activation of Rho family
GTPases, which regulate actin filament assembly, enhanced
CD44 cleavage (Shi et al., 2001). Shedding of CD44 has
also been reported to be induced by Ras, an oncoprotein in-
volved in cell motility and migration. The effect of Ras on
CD44 processing appears to be mediated by members of the
Rho family of GTPases (Kawano et al., 2000). Taken to-
gether, these data suggest that shedding of CD44 is con-
trolled by Ras and Rho GTPases (Cdc42 and Rac1), possi-
bly via regulation of the actin cytoskeleton.
Endogenous metalloproteinases and serine proteinases
have been implicated in the shedding of CD44 based on ab-
rogation of its release by selective pharmacologic inhibitors.
In contrast, selective inhibition of serine proteinases in some
cell systems augments the release of CD44, suggesting that
serine proteinases may control the activity of another class of
enzymes involved in the processing of CD44 (Okamoto et
al., 1999). Cell surface localization as well as activation and
inhibition profiles suggest that the ADAM (a disintegrin and
metalloprotease) family of enzymes may be involved in
CD44 shedding, but at least one particular ADAM family
member, TACE (TNF-
 
 
 
 converting enzyme), has been ex-
cluded as playing a role in the processing of CD44 (Shi et
al., 2001). Membrane type 1 and membrane type 3 metallo-
proteinases (MT1-MMP and MT3-MMP, respectively), on
the other hand, have been shown to be capable of mediating
the processing for CD44. Coexpression of CD44 and either
MT1-MMP or MT3-MMP, but not MT2-, MT4-, and
MT5-MMPs, resulted in shedding of CD44 in human
breast carcinoma cells (Kajita et al., 2001).
 
Consequences of the release of CD44 
from the cell surface
 
The release of CD44 is likely to affect cellular behavior
through multiple mechanisms. First, the released ecto-
domain of the receptor may compete with cell surface
CD44 for ligand binding. The ability of sCD44–Ig fusion
protein to block HA binding suggests that sCD44 can in-
deed antagonize the effect of membrane-bound CD44. In
fact, sCD44 has been used to disrupt endogenous CD44–
HA interactions and thereby promote apoptosis, inhibit
MMP-mediated invasion, and inhibit tumor cell prolifera-
tion (Yu et al., 1997; Peterson et al., 2000; Yu and Stamen-
kovic, 2000). Overexpression of sCD44 is believed to displace
endogenous HA from its membrane-anchored receptors.
The changes in tumor cell growth induced by sCD44–Ig fu-
sion protein were dependent on the ability of sCD44 to
bind HA, indicating that sCD44 can act as a competitive in-
hibitor of endogenous HA–protein interactions (Peterson et
al., 2000). However, soluble forms of CD44 can differ in
their capacity to bind HA. For instance, the affinity of
sCD44 released from lung-derived epithelial tumor cells for
HA varies depending on the stimuli used to induce its re-
lease (unpublished data). Regulation of the affinity of
sCD44 for HA may determine its impact on CD44-depen-
dent processes. Second, cleavage of CD44 might also be a
mechanism to disrupt or prevent CD44-dependent cell–cell
and cell–matrix adhesion. Third, the cleavage of CD44 may
regulate cell migration. Thus, coexpression of CD44 and
wild-type MT1-MMP promoted motility of human breast
cancer cells, whereas mutants of CD44 lacking the MT1-
MMP processing site or pharmacological inhibition of
MMP activity led to suppression of cell migration, support-
ing the concept that cell migration requires cell surface pro-
cessing of CD44.
 
CD44 accumulates as an integral component 
of the matrix
 
sCD44 was previously assumed to be released into body flu-
ids mainly as the result of proteolytic cleavage of cell surface
CD44. However, in vitro, spontaneously released CD44 ap-
pears to be at least partially sequestered through its associa-
tion with the cell-associated matrix, where it can be targeted
for further processing by extracellular proteinases and other
matrix-modifying enzymes such as chondroitinase (Cichy et
al., 2002) (Fig. 1). Release of matrix-associated CD44, as
opposed to membrane CD44, may impact differently on the
behavioral response of cells to conditions of elevated pro-
teolytic activity and matrix remodeling. For example, libera-
tion of CD44 from the matrix is less likely to trigger the in-
tramembrane cleavage of CD44 and production of the
intracellular domain of CD44 (CD44-ICD), which wouldT
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be expected to occur if proteinases targeted membrane
CD44 (Brown et al., 2000).
The accumulation of CD44 released from cells as an inte-
gral component of the matrix suggests that pericellular and
extracellular matrix may be important reservoirs of sCD44.
Digestion with bacteria- and phagocyte-derived proteinases
liberates sCD44 from the matrix (Cichy et al., 2002). Thus,
the disruption of the ECM that occurs in the face of the en-
hanced proteolytic activity associated with infection, inflam-
mation, and tumor metastasis may liberate matrix-associated
as well as transmembrane CD44 and lead to an increase in
fluid phase CD44 as manifested by a rise in levels of sCD44
in body fluids under these conditions (Katoh et al., 1994;
Okamoto et al., 2002). Moreover, accumulation of CD44 as
an integral component of the matrix may provide a protec-
tive mechanism for maintaining the integrity of cellular bar-
riers, such as that surrounding airway epithelium, by com-
peting with cell surface CD44 as a substrate for proteinases
and by competing for pathogen binding. The composition
of the ECM and its organization are major determinants of
environmental signaling that controls cell fate. Previous
studies demonstrated that the transmembrane form of
CD44 plays a role in the assembly of HA-rich pericellular
matrices (Knudson et al., 1996). Based on our recent data
demonstrating that CD44 also accumulates as an integral
component of cellular matrices after it is proteolytically
cleaved from the cell surface (Cichy et al., 2002), it is tempt-
ing to speculate that shedding of CD44 may contribute to
the organization of the ECM. It is generally well accepted
that assembly of the ECM occurs in close proximity to the
cell surface. If CD44 is involved in the formation of the ma-
trix at the cell surface, then shedding of CD44 is likely to be
associated with the deposition and retention of other CD44-
associated molecules into the extracellular milieu. In other
words, pericellular matrix, through shedding of surface re-
ceptors including CD44, may act as a source of ECM or its
nucleation and retention. The broad distribution of CD44,
the ability of a wide variety of CD44-positive cells to shed
the receptor, and the fact that many cells are characterized
by the expression of high levels of CD44 on the cell surface
suggest that shedding of this receptor could potentially re-
sult in significant deposition of ECM components preas-
sembled into sCD44-containing complexes at the cell sur-
face. A role for CD44 in organizing the matrix after it is
released from the cell surface is consistent with the noted ho-
mology of the extracellular domain of CD44 with the family
of proteoglycans with G1 domains that contain link mod-
ules (the HA binding motif).
 
Proteolysis liberates the intracellular cytoplasmic 
domain of CD44 from the membrane
 
Cleavage of the extracellular domain of CD44 can be fol-
lowed by subsequent proteolysis within the transmembrane
domain dependent on presenilin-1, a putative membrane as-
partyl protease (Okamoto et al., 2001; Lammich et al.,
2002). Several substrates for presenilin-1–dependent activity
have been identified, including Notch, E-cadherin, ErbB-4,
and 
 
 
 
-amyloid precursor protein. All of these type-1 trans-
membrane proteins have been demonstrated to undergo
ectodomain shedding, which appears to be required for the
subsequent presenilin-dependent cleavage (Lammich et al.,
2002). Presenilin-dependent proteolysis of CD44 has been
reported to occur at two sites (Fig. 1): one close to the cyto-
plasmic border, leading to the liberation of CD44-ICD, and
another site within the transmembrane domain, resulting in
the extracellular release of the so-called CD44
 
 
 
 peptide.
The latter is reminiscent of the presenilin-dependent pro-
cessing of 
 
 
 
-amyloid precursor protein leading to the release
of amyloid 
 
 
 
 peptide(s) implicated in Alzheimer’s disease
(Lammich et al., 2002). Shedding of CD44 may also play a
role in regulating gene transcription as the result of the liber-
ation of CD44-ICD (Okamoto et al., 2001). CD44-ICD
appears to translocate to the nucleus and promote transcrip-
tion mediated through TPA-responsive elements, including
transcription of CD44 itself, providing a classic feedback
mechanism for regulating CD44 expression.
 
Concluding remarks
 
The multiple products of a single gene, such as CD44, can
take on a variety of forms and functions. Proteolytic process-
ing of CD44 may regulate cell–cell and cell–matrix interac-
tions, and results in the generation of potentially biologically
active fragments. Thus, CD44 exists as a typical transmem-
Figure 1. CD44 exists in three phases: a typical transmembrane 
receptor, a matrix-associated fragment of the extracellular domain, 
and as soluble fragments in the fluid phase. Membrane-anchored 
CD44 can be cleaved by MT1-MMP at the cell surface and is subject 
to subsequent dual intramembraneous cleavage by presenilin-1. 
Presenilin-1–dependent processing of CD44 results in the liberation 
of a cytosolic fragment, CD44-ICD, that can translocate to the 
nucleus to control gene transcription. Proteolysis of membrane-
anchored CD44 results in the release of CD44 preassembled into 
complexes with matrix components or the release of the ectodomain 
that then can accumulate as an integral component of the matrix 
due to association with other matrix components. Alternatively, 
transmembrane CD44 may be proteolytically released from the 
cell surface or synthesized de novo in soluble form. The released 
ectodomain of CD44 can be retained in the ECM by establishing 
physical associations with other matrix components such as fibro-
nectin, HA, and collagen. Exposure of the cell-associated matrix 
to exogenous matrix-modifying enzymes, such as chondroitinase, 
and leukocyte- or bacterial-derived proteinases generated as the 
result of infection, inflammation, or tumor metastasis can lead to
the enhanced release of sCD44 from the matrix and, in the face of 
high local concentrations of proteinases, the degradation of sCD44.T
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brane receptor, a matrix-associated extracellular domain
fragment, and as a soluble fragment of the extracellular do-
main found in the circulation and other body fluids. In ad-
dition, a proteolytic fragment of the cytoplasmic domain of
CD44 can be released intracellularly and translocated to the
nucleus. Molecular genetic approaches can be used to gener-
ate mice expressing sCD44 in the absence of transmembrane
CD44, expressing transmembrane CD44 resistant to pro-
teolytic processing, and overexpressing CD44-ICD. Such
studies will be required to better understand the role of pro-
teolytic fragments of CD44 in homeostasis and disease. Fu-
ture studies are also required to determine the extent to
which other cell surface receptors are subject to similar pro-
cessing events.
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